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EDITORIAL Open Access
Bronchiectasis: an emerging
global epidemic
Sanjay H. Chotirmall1* and James D. Chalmers2
Abstract
Bronchiectasis has an increasing profile within respiratory medicine. This chronic and irreversible airways disease is
common but suffers from a lack of evidenced based therapy for patients and, a lack of understanding of its
inherent heterogeneity. Research focused on bronchiectasis must therefore be prioritized if we are to adequately
address this evolving clinical problem. This special issue on bronchiectasis focuses on its clinical, microbiological
and therapeutic aspects. By bringing together a unique collection of original research and review articles, we hope
this issue will showcase international research efforts, encourage future research collaborations and stimulate
debate. In doing so, we hope to bring greater attention to the urgent need for sustained investment into focused,
dedicated and collaborative research platforms in bronchiectasis, an emerging “global epidemic”.
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Editorial
Bronchiectasis is experiencing a clinical and research re-
naissance. This emerging epidemic of chronic and progres-
sive immune-infective-inflammatory airway destruction
results in a vicious cycle of repeated exacerbations and irre-
versible damage that now clearly necessitates greater global
focus and investment. The recent publication of the first
international guidelines for its management is welcome,
particularly as its prevalence and recognition continues to
rise [1–3]. Over the forthcoming years, international health
systems are likely to face great challenges in managing this
group of patients and their associated costs. Therefore, it
appears logical that more research, increased therapeutic
trials and improved specialist services should be prioritised.
Importantly, the clear need for greater bronchiectasis-
focused research is further evidenced by the fact that no
single licensed therapy can yet be recommended for pa-
tients. This is despite the large numbers of trialled agents
necessitating re-consideration of our approach, research
strategy, clinical focus and understanding of the disease’s
inherent heterogeneity [4]. Significant knowledge gaps per-
sist in key areas of disease including aetiology, pathogenesis
and microbial infection. The rising profile of bronchiectasis
is welcome. If we are to effect the true impact of this, we
must continue to develop and curate large datasets across
international populations to inform our clinical practice
and importantly our research [5–7].
As academic respiratory research enters unchartered ter-
ritory; one plagued by the challenge of overlap syndromes,
the application of new “omics” technologies, improved
tools to understand disease endo-phenotypes and a com-
plex arena of bioinformatics, the relevance of these devel-
oping areas to bronchiectasis focused research must be
considered [3, 8–10]. The quality and quantity of research
in the field should increase in parallel to ensure a secure
future for our patients and the care they receive. Airway in-
fection remains a major challenge in bronchiectasis and
emerging culture-independent sequencing technologies
provide further insight into its complexity [5–7]. A deeper
understanding of the functional implications of airway
microbes in a lung affected by bronchiectasis is necessary
and this goes beyond bacteria to include non-tuberculous
mycobacterial species, viruses and even fungi [11–14].
To add to the growing focus and interest in bronchiec-
tasis, we dedicate this special issue to further promote
its resurgence. This issue includes six original and three
commissioned review articles organized into three
thematic areas of importance: (1) clinical disease (2) airway
infection and (3) lung transplantation.
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Clinical disease
In this special issue, the clinical aspects of bronchiectasis
are covered from both the physician and patient
perspective. The authoritative review by Schäfer and
colleagues reviews bronchiectasis pathogenesis, its im-
aging and clinical characteristics from both a cystic fibro-
sis (CF) and non-CF perspective across a diverse range of
aetiologies [15]. In a patient focused article, Hester et al.
address the issue of adherence to the multi-modal treat-
ment options used in the care of bronchiectasis patients
by reviewing the provision of and requirement for patient
education [16]. Minimal work to date has been performed
in bronchiectasis focused in this area especially when
compared to other chronic respiratory conditions such as
asthma and chronic obstructive pulmonary disease
(COPD). The information deficits uncovered in this quali-
tative approach clearly represent one of the key barriers to
the implementation of bronchiectasis self-management.
Further original qualitative work is provided by Dudgeon
et al. whose study focused on the patient’s perspective of
health-related quality of life (QOL) [17]. Semi-structured
interviews elucidated that bronchiectasis-related symp-
toms are highly individual and variable, a feature that
current available treatment and QOL tools do not
adequately capture.
Airway infection
Infection is an established driver of exacerbations and
disease progression in bronchiectasis, however, while
acknowledged, geographic variation in disease has not
been previously reviewed. Chandrasekaran et al. per-
formed a comprehensive review of this understudied
area of disease heterogeneity that has emerged in recent
times, further evidenced by the contrasting results from
the RESPIRE 1 and 2 trials performed across geographic-
ally distinct regions [18–21]. Three original articles fo-
cused on non-tuberculous mycobacteria (NTM), viruses
and paediatric microbiomes are further important addi-
tions to this special issue. Lim and colleagues illustrate
that NTM profiles in an Asian setting (Singapore) are
unique with M. abscessus commonest and associated
with high rates of pulmonary tuberculosis, itself a major
contributor to the bronchiectasis burden in Asia [22].
Mitchell et al. examined viruses in stable and exacerbat-
ing bronchiectasis in a pilot study [23]. The strength of
this work is a weakness of prior studies in this area: an
assessment of viral prevalence in the stable clinical state.
The authors detect viruses at high frequency from re-
spiratory secretions and exhaled breath, even in the
stable state and with the absence of clinical symptoms,
questioning their ‘true’ relevance in bronchiectasis.
Longitudinal studies are clearly required including those
focused on the host ‘virome’ to provide greater clarity to
these findings. In contrast to the ‘virome’, the microbiome
in bronchiectasis has been better studied and Masekela
et al. further add to this by assessing the lung microbiome
in children with human immunodeficiency virus (HIV)-re-
lated bronchiectasis, a field where minimal data currently
exists [24]. This study showed a less diverse and largely
heterogeneous microbiome dominated by Proteobacteria
when compared to a small control group with CF illustrat-
ing the contrasting pathologies leading to bronchiectasis
in the context of susceptibility to infection.
Lung transplantation
Lung transplantation is a viable therapeutic option in
bronchiectasis and only a few publications have reported
on this management strategy for end-stage disease. This
issue includes two original articles, one assessing trans-
plant outcomes and the other international practice. Birch
et al. report the outcomes of lung transplantation over a
period of more than two decades from a major European
transplant referral centre [25]. The data show that lung
transplantation for bronchiectasis is useful, associated
with good lung function and importantly survival, which
is comparable to other bilateral lung transplant recipients
suffering from other causes of end-stage respiratory fail-
ure. Tissot and colleagues focused on the difficult issue of
NTM infection in CF patients suitable for transplant list-
ing and ascertaining current international practice [26].
NTM infection is complex, therapeutically challenging
and associated with poorer disease outcome in CF how-
ever the suitability of such patients for lung transplant-
ation is poorly characterized. Data in this issue illustrate
that across international transplant centres a lack of stan-
dards exists, leading to variable practices. Therefore, an
urgent need for better quality data to aid clinical decision
making exists to inform equitable access to lung trans-
plant for NTM-infected CF patients.
The once silent bronchiectasis epidemic continues to
gain momentum. Its recent global resurgence necessi-
tates dedicated research and sustained investment if we
are to improve the clinical care delivered and our under-
standing of its pathogenesis. This special issue dedicated
to bronchiectasis aims to reaffirm its growing profile
through the varied collection of articles focusing on its
clinical, microbiological and therapeutic aspects. The
time has come to control the evolving bronchiectasis
epidemic, and to do so requires a collective manifesto of
using evidenced based research to deliver safe and
effective therapy to suffering patients with this life-
threatening disease.
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